Clinical effects of mepolizumab in patients with severe eosinophilic asthma according to background therapy: A meta-analysis

Njira Lugogo; Mark C. Liu; Ian Pavord; Patrick D. Mitchell; Steven G. Smith; Stephen Mallett; Frank C. Albers; Eric S. Bradford; Steven W. Yancey; Elisabeth H. Bel

doi:10.1016/j.jaip.2021.05.024

Clinical effects of mepolizumab in patients with severe eosinophilic asthma according to background therapy: A meta-analysis

Njira Lugogo, Mark C. Liu, Ian Pavord, Patrick D. Mitchell, Steven G. Smith, Stephen Mallett, Frank C. Albers, Eric S. Bradford, Steven W. Yancey, Elisabeth H. Bel

School of Medicine

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	3506-3509.e3
Journal	Journal of Allergy and Clinical Immunology: In Practice
Volume	9
Issue number	9
DOIs	https://doi.org/10.1016/j.jaip.2021.05.024
State	Published - Sep 2021

ASJC Scopus subject areas

Immunology and Allergy

Access to Document

10.1016/j.jaip.2021.05.024

Cite this

Lugogo, N., Liu, M. C., Pavord, I., Mitchell, P. D., Smith, S. G., Mallett, S., Albers, F. C., Bradford, E. S., Yancey, S. W., & Bel, E. H. (2021). Clinical effects of mepolizumab in patients with severe eosinophilic asthma according to background therapy: A meta-analysis. Journal of Allergy and Clinical Immunology: In Practice, 9(9), 3506-3509.e3. https://doi.org/10.1016/j.jaip.2021.05.024

Lugogo, N, Liu, MC, Pavord, I, Mitchell, PD, Smith, SG, Mallett, S, Albers, FC, Bradford, ES, Yancey, SW & Bel, EH 2021, 'Clinical effects of mepolizumab in patients with severe eosinophilic asthma according to background therapy: A meta-analysis', Journal of Allergy and Clinical Immunology: In Practice, vol. 9, no. 9, pp. 3506-3509.e3. https://doi.org/10.1016/j.jaip.2021.05.024

@article{1a08909cef8a44a2bf8148ecb49beb6b,

title = "Clinical effects of mepolizumab in patients with severe eosinophilic asthma according to background therapy: A meta-analysis",

author = "Njira Lugogo and Liu, {Mark C.} and Ian Pavord and Mitchell, {Patrick D.} and Smith, {Steven G.} and Stephen Mallett and Albers, {Frank C.} and Bradford, {Eric S.} and Yancey, {Steven W.} and Bel, {Elisabeth H.}",

note = "Funding Information: Editorial support (in the form of writing assistance, including preparation of the draft manuscript under the direction and guidance of the authors, collating and incorporating authors' comments for each draft, assembling tables and figures, grammatical editing and referencing) was provided by Roisin McCorkell, MSc, at Fishawack Indicia Ltd, United Kingdom, part of Fishawack Health, and was funded by GlaxoSmithKline. S. G. Smith, S. Mallett, F. C. Albers, E. S. Bradford, and S. W. Yancey were involved in the conception or design of the analyses; N. Lugogo, M. C. Liu, and I. Pavord were involved in the acquisition of data; and all authors were involved in analyzing or interpreting the data and drafting the work or revising it critically for important intellectual content. All authors gave final approval of the version to be published, and agreed to be accountable for all aspects of the work. Anonymized individual participant data from the studies listed within this publication and the associated documents can be requested for further research from www.clinicalstudydatarequest.com . ",

year = "2021",

month = sep,

doi = "10.1016/j.jaip.2021.05.024",

language = "English (US)",

volume = "9",

pages = "3506--3509.e3",

journal = "Journal of Allergy and Clinical Immunology: In Practice",

issn = "2213-2198",

publisher = "Elsevier",

number = "9",

}

TY - JOUR

T1 - Clinical effects of mepolizumab in patients with severe eosinophilic asthma according to background therapy

T2 - A meta-analysis

AU - Lugogo, Njira

AU - Liu, Mark C.

AU - Pavord, Ian

AU - Mitchell, Patrick D.

AU - Smith, Steven G.

AU - Mallett, Stephen

AU - Albers, Frank C.

AU - Bradford, Eric S.

AU - Yancey, Steven W.

AU - Bel, Elisabeth H.

N1 - Funding Information: Editorial support (in the form of writing assistance, including preparation of the draft manuscript under the direction and guidance of the authors, collating and incorporating authors' comments for each draft, assembling tables and figures, grammatical editing and referencing) was provided by Roisin McCorkell, MSc, at Fishawack Indicia Ltd, United Kingdom, part of Fishawack Health, and was funded by GlaxoSmithKline. S. G. Smith, S. Mallett, F. C. Albers, E. S. Bradford, and S. W. Yancey were involved in the conception or design of the analyses; N. Lugogo, M. C. Liu, and I. Pavord were involved in the acquisition of data; and all authors were involved in analyzing or interpreting the data and drafting the work or revising it critically for important intellectual content. All authors gave final approval of the version to be published, and agreed to be accountable for all aspects of the work. Anonymized individual participant data from the studies listed within this publication and the associated documents can be requested for further research from www.clinicalstudydatarequest.com .

PY - 2021/9

Y1 - 2021/9

UR - http://www.scopus.com/inward/record.url?scp=85108793157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85108793157&partnerID=8YFLogxK

U2 - 10.1016/j.jaip.2021.05.024

DO - 10.1016/j.jaip.2021.05.024

M3 - Article

C2 - 34111572

AN - SCOPUS:85108793157

SN - 2213-2198

VL - 9

SP - 3506-3509.e3

JO - Journal of Allergy and Clinical Immunology: In Practice

JF - Journal of Allergy and Clinical Immunology: In Practice

IS - 9

ER -

Clinical effects of mepolizumab in patients with severe eosinophilic asthma according to background therapy: A meta-analysis

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this